Want to see TSE:BUX full AI Analyst Report?
BioMark Diagnostics (BUX) AI Stock Analysis
BioMark Diagnostics
(CNQX:BUX)
The score is driven primarily by weak financial performance: steep TTM revenue decline, persistent large losses, and ongoing cash burn alongside elevated leverage. Technicals add further pressure with a bearish trend (price below key moving averages and negative MACD), though oversold RSI/Stoch slightly temper the outlook. Valuation provides limited support because the negative P/E reflects loss-making operations and no dividend yield is available.
BioMark Diagnostics (BUX) vs. iShares MSCI Canada ETF (EWC)
- Market Cap
- CAD 50.05M
- Dividend Yield
- ―
- Average Volume (3M)
- 8,109
- Price to Earnings (P/E)
- -34.8
- Beta (1Y)
- 0.13
- Revenue Growth
- -82.05%
- EPS Growth
- 23.73%
- Country
- Canada
- Employees
- 9
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Diagnostics & Research
BioMark Diagnostics Business Overview & Revenue Model
Company Description
BioMark Diagnostics Inc. is an oncology specialist, developing advanced diagnostic tools for cancer to enable early detection, continuous patient monitoring, and the assessment of initial treatment efficacy. The firm holds a research partnership with...
BioMark Diagnostics Financial Statement Overview
Summary
Financials indicate a high-risk profile: TTM revenue fell sharply (~-53% YoY), profitability is deeply negative (including negative gross profit) with large operating losses, and operating/free cash flow are negative across all periods. While equity is currently positive versus prior negative-equity years, leverage is now elevated (debt a little over ~2x equity), increasing financing and dilution risk.
Income Statement
9Very NegativeBalance Sheet
28NegativeCash Flow
12Very Negative| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 59.79K | 59.79K | 154.22K | 163.22K | 43.93K | 0 |
| Gross Profit | -222.04K | -322.49K | 154.22K | 163.22K | 43.93K | -13.69K |
| EBITDA | -1.43M | -1.49M | -1.46M | -919.05K | -1.22M | -1.08M |
| Net Income | -1.48M | -1.48M | -1.93M | -1.43M | -1.45M | -1.09M |
Balance Sheet | ||||||
| Total Assets | 1.86M | 1.86M | 3.13M | 1.09M | 1.47M | 952.94K |
| Cash, Cash Equivalents and Short-Term Investments | 1.01M | 1.01M | 2.48M | 156.75K | 382.71K | 877.68K |
| Total Debt | 724.86K | 724.86K | 454.16K | 1.55M | 1.05M | 119.32K |
| Total Liabilities | 1.53M | 1.53M | 1.39M | 1.70M | 2.11M | 1.03M |
| Stockholders Equity | 331.06K | 331.06K | 1.74M | -609.61K | -635.69K | -79.09K |
Cash Flow | ||||||
| Free Cash Flow | -1.09M | -1.09M | -1.10M | -986.91K | -1.26M | -455.55K |
| Operating Cash Flow | -1.09M | -1.09M | -1.09M | -982.52K | -1.20M | -455.55K |
| Investing Cash Flow | -396.05K | -396.05K | -3,533 | -4,394 | -59.20K | -3,200 |
| Financing Cash Flow | -377.83K | -377.83K | 3.42M | 1.07M | 768.16K | 724.63K |
BioMark Diagnostics Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:BUX, the sentiment is Negative. The current price of 0.47 is below the 20-day moving average (MA) of 0.50, below the 50-day MA of 0.51, and below the 200-day MA of 0.55, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 38.39 is Neutral, neither overbought nor oversold. The STOCH value of 54.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:BUX.
BioMark Diagnostics Peers Comparison
Overall Rating
TSE:TELO46Neutral- TSE:BUX42Neutral
TSE:EDT40Underperform
TSE:SONA40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| TSE:TELO | 46Neutral | CAD 5.02M | -2.17 | 295.03% | ― | ― | 25.57% |
| TSE:BUX | 42Neutral | CAD 50.05M | -34.81 | -250.77% | ― | -82.05% | 23.73% |
| TSE:EDT | 40Underperform | CAD 303.48M | -8.01 | 51.23% | ― | 1.46% | -64.85% |
| TSE:SONA | 40Underperform | CAD 34.38M | -13.08 | 448.05% | ― | ― | 24.65% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TSE:BUX | BioMark Diagnostics | 0.47 | 0.13 | 38.24% | |
| TSE:EDT | Spectral Medical (Edtxf) | 1.03 | -0.44 | -29.93% | |
| TSE:TELO | Telo Genomics | 0.05 | 0.00 | 0.00% | |
| TSE:SZLS.H | Stagezero Life Sciences | 0.04 | 0.00 | 0.00% | |
| TSE:ZYUS | Zyus Life Sciences Corporation | 0.37 | -0.33 | -47.14% | |
| TSE:SONA | Sona Nanotech, Inc | 0.28 | -0.33 | -54.10% |
BioMark Diagnostics Corporate Events
BioMark to Spotlight Metabolomics Platform at Quebec Life Sciences Conferences
PositiveBioMark Diagnostics will participate in the MSACL 2026 and BIOHorizon 2026 conferences in Quebec in early October, engaging clinical mass spectrometry experts, decision-makers, and investors. The company plans to highlight its metabolomics-based liqu...
BioMark Wins Global Scientific Backing for AI-Driven Lung Cancer Blood Test
PositiveBioMark Diagnostics has reported significant scientific momentum for its metabolomics-based liquid biopsy platform for early lung cancer detection, with five peer-reviewed studies published in the past nine months. The company’s blood-based ass...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 06, 2026